Spotlight on Cardiology

Credits: 1.00 CME / MOC / CNE
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor
Bart Duell, MD
American Heart Association

W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

Start

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Cardiology Presentations

1.00 CME / MOC / CNE
American Heart Association
W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

W.O.W. Why HOw and When to measure Lipoprotein(a): A Clinically Relevant Cardiovascular Risk Factor

Start

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

Activity Details

Free CME/MOC/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC credit(s)
1.0 Contact Hour(s)
Released: September 13, 2021
Expires: September 12, 2022
60 minutes to complete

Accredited By

Target Audience

Includes but is not limited to cardiologists, interventional cardiologists, preventative cardiologists, LDL specialists, nurse practitioners, physician assistants, nurses, etc.

Learning Objectives

  1. Define Lipoprotein(a)
  2. Describe WHY Lipoprotein(a) should be measured
  3. Explain HOW to measure Lipoprotein(a)
  4. Indicate WHEN to measure Lipoprotein(a)

Activity Description

This webinar will cover the principles of why, how and when clinicians should consider measuring Lipoprotein(a) levels. It will be based on the latest available scientific evidence and support the ongoing guidelines/methods being used in the field.

Statement of Educational Need

  • Clinicians lack knowledge about why they should measure Lipoprotein(a)
  • Clinicians do not know how to measure Lipoprotein(a)
  • Clinicians do not recognize when to measure Lipoprotein(a)

Faculty

Bart Duell, MD
Professor of Medicine
Division of Cardiovascular Medicine, School of Medicine
Oregon Science & Health University
Portland, Oregon

Disclosure: Akcea


Gissette Reyes-Soffer, MD
Herbert Irving Assistant Professor of Medicine
Columbia University Medical Center
College of Physicians and Surgeons
New York, New York

Disclosure: Amgen, Inc.


Pia Kamstrup, MD, PhD
Head of Department of Clinical Biochemistry
Herlev and Gentofte Hospital
Copenhagen University Hospital
Copenhagen, Denmark

Disclosure: None reported relevant to this webinar.


Calvin Yeang, MD, PhD
Cardiologist
UC San Diego Health
San Diego, California

Disclosure: Kaneka, Ionis Pharmaceuticals

Conflict of Interest Policy/Disclosure Statement

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity. It is the CE activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

Statement of Commercial Support

This activity is supported by an educational grant from Kaneka Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Please contact Sheila Jackson at the American Heart Association at Sheila.Jackson@heart.org with any questions.

1.25 CME
Vindico Medical Education
Addressing Disparities in Care: Focus on Hyperlipidemia – In Case You Missed the American College of Cardiology Meeting

Addressing Disparities in Care: Focus on Hyperlipidemia – In Case You Missed the American College of Cardiology Meeting

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Educational Partner:

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the impact of gender and race on CVD screening, management, and outcomes.
  • Assess the latest data regarding the impact of oral, non-statin therapies on LDL-C and how they may benefit women and/or minority populations.
  • Assess the latest recommendations regarding triglyceride-lowering therapies that confer benefit on CV outcomes for patients with atherosclerotic CVD.

Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Prevalence of CVD is increasing disproportionately in Black and Hispanic populations as well as in women. Dyslipidemia is a major risk factor for adverse CV outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). Similarly, as many as 22% of adults have high triglyceride levels, according to data from 2013-2016. While many patients with elevated LDL-C and triglyceride levels benefit from statin therapy, about 10% to 30% experience statin intolerance or dose-limiting toxicities, leaving them at risk for adverse CV events. Add-on medications may further reduce LDL-C and triglyceride levels for these patients. In this continuing education activity, expert clinicians discuss how to manage patients with elevated LDL-C and hypertriglyceridemia as well as provide strategies to address the racial and gender disparities observed in the care of patients with CVD.

Agenda

Introduction - Karol E. Watson, MD, PhD, FACC, FAHA
Racial and Gender Disparities in CVD - Karol E. Watson, MD, PhD, FACC, FAHA
Advances in LDL-C Reduction: Implications for Treatment and Safety - Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Residual Cardiovascular Risk Reduction - Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Clinical Cases - Moderated by Karol E. Watson, MD, PhD, FACC, FAHA

Activity Chair

Karol E. Watson, MD, PhD, FACC, FAHA
Professor of Medicine/Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

Faculty

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Member
Louisiana Governor’s COVID-19 Health Equity Task Force
Louisiana Vaccine Action Collaborative (VAC)
New Orleans, LA

Disclosure: Consulting Fee: Alnylam, Amgen, Medtronic, Novartis


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Disclosure: Consulting Fee: Amgen, Esperion, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education and Association of Black Cardiologists Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Amarin Pharma Inc. and Esperion Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Association of Black Cardiologists continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Association of Black Cardiologists. Neither Vindico Medical Education, Association of Black Cardiologists nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Educational Partner:

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with cardiovascular disease (CVD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the impact of gender and race on CVD screening, management, and outcomes.
  • Assess the latest data regarding the impact of oral, non-statin therapies on LDL-C and how they may benefit women and/or minority populations.
  • Assess the latest recommendations regarding triglyceride-lowering therapies that confer benefit on CV outcomes for patients with atherosclerotic CVD.

Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Prevalence of CVD is increasing disproportionately in Black and Hispanic populations as well as in women. Dyslipidemia is a major risk factor for adverse CV outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). Similarly, as many as 22% of adults have high triglyceride levels, according to data from 2013-2016. While many patients with elevated LDL-C and triglyceride levels benefit from statin therapy, about 10% to 30% experience statin intolerance or dose-limiting toxicities, leaving them at risk for adverse CV events. Add-on medications may further reduce LDL-C and triglyceride levels for these patients. In this continuing education activity, expert clinicians discuss how to manage patients with elevated LDL-C and hypertriglyceridemia as well as provide strategies to address the racial and gender disparities observed in the care of patients with CVD.

Agenda

Introduction - Karol E. Watson, MD, PhD, FACC, FAHA
Racial and Gender Disparities in CVD - Karol E. Watson, MD, PhD, FACC, FAHA
Advances in LDL-C Reduction: Implications for Treatment and Safety - Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Residual Cardiovascular Risk Reduction - Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Clinical Cases - Moderated by Karol E. Watson, MD, PhD, FACC, FAHA

Activity Chair

Karol E. Watson, MD, PhD, FACC, FAHA
Professor of Medicine/Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Co-Director, UCLA Program in Preventive Cardiology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

Faculty

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Member
Louisiana Governor’s COVID-19 Health Equity Task Force
Louisiana Vaccine Action Collaborative (VAC)
New Orleans, LA

Disclosure: Consulting Fee: Alnylam, Amgen, Medtronic, Novartis


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC

Disclosure: Consulting Fee: Amgen, Esperion, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education and Association of Black Cardiologists Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Amarin Pharma Inc. and Esperion Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Association of Black Cardiologists continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Association of Black Cardiologists. Neither Vindico Medical Education, Association of Black Cardiologists nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / CNE / CPE
AcademicCME
Advances in Patient-Controlled On-Demand Treatment of Paroxysmal Supraventricular Tachycardia

Advances in Patient-Controlled On-Demand Treatment of Paroxysmal Supraventricular Tachycardia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 CNE Contact Hour(s)
1.0 CPE Contact Hour(s) (CEUs)
Released: June 3, 2021
Expires: June 2, 2022
60 minutes to complete

Accredited By

Target Audience

The target audience includes interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians who manage patients with PSVT.

Learning Objectives

  1. Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
  2. Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
  3. Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
  4. Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves

Activity Description

Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.

AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with paroxysmal supraventricular tachycardia (PSVT).

Agenda

  1. PSVT: Disease Burden
  2. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
    1. The NODE-301 and RAPID Phase 3 Trials
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient-Actuated Therapy for PSVT
  4. Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
  5. Expert Panel Discussion

Faculty

Paul Dorian, MD
Professor of Medicine and Pharmacology
University of Toronto
St Michael’s Hospital
Toronto, Ontario, Canada


Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Bruce Stambler, MD
Cardiology and Electrophysiology
Piedmont Heart Institute
Atlanta, Georgia

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals

Paul Dorian, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Bruce Stambler, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit(s)™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
    • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a "certificate of completion".
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 CNE Contact Hour(s)
1.0 CPE Contact Hour(s) (CEUs)
Released: June 3, 2021
Expires: June 2, 2022
60 minutes to complete

Accredited By

Target Audience

The target audience includes interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians who manage patients with PSVT.

Learning Objectives

  1. Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
  2. Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
  3. Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
  4. Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves

Activity Description

Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.

AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with paroxysmal supraventricular tachycardia (PSVT).

Agenda

  1. PSVT: Disease Burden
  2. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
    1. The NODE-301 and RAPID Phase 3 Trials
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient-Actuated Therapy for PSVT
  4. Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
  5. Expert Panel Discussion

Faculty

Paul Dorian, MD
Professor of Medicine and Pharmacology
University of Toronto
St Michael’s Hospital
Toronto, Ontario, Canada


Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Bruce Stambler, MD
Cardiology and Electrophysiology
Piedmont Heart Institute
Atlanta, Georgia

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals

Paul Dorian, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Bruce Stambler, MD
Consultant/Advisor: Milestone Pharmaceuticals, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit(s)™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
    • CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    • CME and CNE credit will be issued appropriate certificate of completion.
    • Others may request a "certificate of completion".
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

0.50 CME / MOC
Vindico Medical Education
Improving Cardiovascular Outcomes by Decreasing Residual Risk: Take the Wheel of Knowledge Challenge

Improving Cardiovascular Outcomes by Decreasing Residual Risk: Take the Wheel of Knowledge Challenge

Start

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/
ABIM MOC
Released: February 12, 2021
Expires: February 11, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists, internists, and other health care professionals involved in the management of patients with, or at risk for cardiovascular disease.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Utilize appropriate methods to assess residual risk in patients with controlled low-density lipoprotein cholesterol (LDL-C).
  • Evaluate the latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention.
  • Identify patients who may benefit from additional treatment to reduce cardiovascular risk despite the management of other risk factors and manage them accordingly.

Activity Description

Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. Increasingly, cardiologists have recognized that patients with hypertriglyceridemia experience residual CVD risk and adverse cardiovascular events. Cardiologists and other health care professionals are now rethinking their treatment regimens in light of new findings from cardiovascular outcomes trials. In addition, new evidence continues to emerge regarding cardioprotective mechanisms that underlie newer medications for CVD risk reduction. In this Wheel of Knowledge Challenge, an interactive quiz of knowledge and confidence, your knowledge will be tested on the latest clinical developments and management strategies for patients with, or at risk for, cardiovascular disease. This medical education program will address methods for assessing residual risk in patients with controlled LDL-C. The latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention are also considered, along with methods for identifying patients who may benefit from additional treatment to reduce cardiovascular risk.

Faculty

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC


Disclosure:

Consulting Fee: Amgen, Esperion

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, February 12, 2021 to February 11, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/
ABIM MOC
Released: February 12, 2021
Expires: February 11, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists, internists, and other health care professionals involved in the management of patients with, or at risk for cardiovascular disease.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Utilize appropriate methods to assess residual risk in patients with controlled low-density lipoprotein cholesterol (LDL-C).
  • Evaluate the latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention.
  • Identify patients who may benefit from additional treatment to reduce cardiovascular risk despite the management of other risk factors and manage them accordingly.

Activity Description

Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. Increasingly, cardiologists have recognized that patients with hypertriglyceridemia experience residual CVD risk and adverse cardiovascular events. Cardiologists and other health care professionals are now rethinking their treatment regimens in light of new findings from cardiovascular outcomes trials. In addition, new evidence continues to emerge regarding cardioprotective mechanisms that underlie newer medications for CVD risk reduction. In this Wheel of Knowledge Challenge, an interactive quiz of knowledge and confidence, your knowledge will be tested on the latest clinical developments and management strategies for patients with, or at risk for, cardiovascular disease. This medical education program will address methods for assessing residual risk in patients with controlled LDL-C. The latest clinical evidence regarding cardiovascular outcomes trials and the implications for primary and secondary prevention are also considered, along with methods for identifying patients who may benefit from additional treatment to reduce cardiovascular risk.

Faculty

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Director, Seinsheimer Cardiovascular Health Program
The Medical University of South Carolina
Charleston, SC


Disclosure:

Consulting Fee: Amgen, Esperion

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, February 12, 2021 to February 11, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Amarin Pharma Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

0.50 CME
Vindico Medical Education
Calcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF

Calcitropes, Myotropes, and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 27, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with heart failure with reduced ejection fraction (HFrEF).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the benefits and pitfalls of traditional inotropic agents and their impact on long-term outcomes in the treatment of HFrEF.
  • Evaluate new terminology with mechanistic nomenclature to foster effective communication and highlight novel therapeutic agents to improve myocardial contractility and function.
  • Assess the unique mechanisms of action of cardiac myotropes and clinical evidence regarding their safety and efficacy in the treatment of HFrEF.

Activity Description

Reductions in myocardial contractile function and increases in cardiac wall stress can trigger multiple interrelated compensatory mechanisms, including neurohormonal activation and ventricular remodeling. These result in increased myocardial oxygen demand and reduced contractile efficiency, promoting additional myocardial injury and cardiomyocyte death. These effects perpetuate a negative feedback cycle that results in symptomatic heart failure with a reduced ejection fraction (HFrEF) and, eventually, death.

Multiple lifesaving therapies, including angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mineralocorticoid antagonists; beta blockers; and, most recently, dual-acting angiotensin receptor-neprilysin inhibitors, have been developed to address the neurohormonal activation in HFrEF. However, these therapies do not directly address the central driver in the pathogenesis of HFrEF—decreased myocardial contractility—resulting in decrease systolic function. The use of conventional inotropic agents may increase morbidity as well as mortality and are associated with a higher risk of ventricular arrhythmia, atrial fibrillation, hypotension, induced myocardial ischemia, increased myocardial oxygen consumption, and direct myocyte toxicity due to an intracellular calcium overload.

Pharmacologic agents that improve myocardial performance can be classified as calcitropes that alter intracellular calcium concentrations, myotropes that affect the molecular motor and scaffolding, and mitotropes that influence the myocardial energetics. In this educational activity, faculty will discuss the latest data regarding newer agents in development that can directly enhance myocardial contractility, without increasing cardiac workload or oxygen consumption.

Agenda

Matters of the Heart: Unmet Needs in Heart Failure With Reduced Ejection Fraction (HFrEF)

Emerging HFrEF Therapies: A Look at the Clinical Evidence

Activity Chair

John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP(UK)
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA

Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis

Faculty

Mitchell A. Psotka, MD, PhD, FACC, FHFSA
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA

Consulting Fee: Amgen, Cytokinetics, Windtree

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Cytokinetics, Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 27, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is cardiologists and other health care professionals involved in the management of patients with heart failure with reduced ejection fraction (HFrEF).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the benefits and pitfalls of traditional inotropic agents and their impact on long-term outcomes in the treatment of HFrEF.
  • Evaluate new terminology with mechanistic nomenclature to foster effective communication and highlight novel therapeutic agents to improve myocardial contractility and function.
  • Assess the unique mechanisms of action of cardiac myotropes and clinical evidence regarding their safety and efficacy in the treatment of HFrEF.

Activity Description

Reductions in myocardial contractile function and increases in cardiac wall stress can trigger multiple interrelated compensatory mechanisms, including neurohormonal activation and ventricular remodeling. These result in increased myocardial oxygen demand and reduced contractile efficiency, promoting additional myocardial injury and cardiomyocyte death. These effects perpetuate a negative feedback cycle that results in symptomatic heart failure with a reduced ejection fraction (HFrEF) and, eventually, death.

Multiple lifesaving therapies, including angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mineralocorticoid antagonists; beta blockers; and, most recently, dual-acting angiotensin receptor-neprilysin inhibitors, have been developed to address the neurohormonal activation in HFrEF. However, these therapies do not directly address the central driver in the pathogenesis of HFrEF—decreased myocardial contractility—resulting in decrease systolic function. The use of conventional inotropic agents may increase morbidity as well as mortality and are associated with a higher risk of ventricular arrhythmia, atrial fibrillation, hypotension, induced myocardial ischemia, increased myocardial oxygen consumption, and direct myocyte toxicity due to an intracellular calcium overload.

Pharmacologic agents that improve myocardial performance can be classified as calcitropes that alter intracellular calcium concentrations, myotropes that affect the molecular motor and scaffolding, and mitotropes that influence the myocardial energetics. In this educational activity, faculty will discuss the latest data regarding newer agents in development that can directly enhance myocardial contractility, without increasing cardiac workload or oxygen consumption.

Agenda

Matters of the Heart: Unmet Needs in Heart Failure With Reduced Ejection Fraction (HFrEF)

Emerging HFrEF Therapies: A Look at the Clinical Evidence

Activity Chair

John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP(UK)
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA

Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis

Faculty

Mitchell A. Psotka, MD, PhD, FACC, FHFSA
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA

Consulting Fee: Amgen, Cytokinetics, Windtree

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Cytokinetics, Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / CNE / CPE
AcademicCME
Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Managing Hemorrhagic Complications and Bleeding Risks Associated with Platelet P2Y12 Inhibitor Therapy

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians, including nurses, NPs, PAs, and pharmacists who manage patients with P2Y12 inhibitor-related bleeding risks.

Learning Objectives

  1. Review the scientific basis for benefit from P2Y12 inhibition as well as the bleeding risks that result from therapy and understand the known epidemiology of clinically significant bleeding complications with these agents
  2. Analyze and understand the different perspectives of various specialists on the chronic use of P2Y12 inhibitor therapy
  3. Review current management strategies for P2Y12 inhibitor-associated bleeding risks, as well as therapies still in development
  4. Review in detail the rationale and methodology of a phase 3 clinical trial that identifies patients suitable for ticagrelor reversal and follow its execution as the science of managing patients with ticagrelor-associated hemorrhage and procedural bleeding risk

Activity Description

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT)—the combination of aspirin with an oral P2Y12 receptor antagonist—is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y12 receptor antagonists that are in use are clopidogrel, prasugrel, and ticagrelor.

An unavoidable limitation of all three oral P2Y12 receptor antagonists is increased bleeding risk from platelet inhibition, which persists for several days after drug cessation. Establishment of hemostasis can be challenging in patients with major bleeding, such as intracranial or gastrointestinal hemorrhage. In addition, urgent invasive procedures, especially emergency procedures, are associated with an increased risk of periprocedural bleeding. If an emergency procedure is indicated, the surgeon or proceduralist must proceed while accepting the increased bleeding risk, often after empirically providing platelet transfusions, despite the ineffectiveness of such transfusions in reversing the antiplatelet effects of P2Y12 inhibitors. If an urgent procedure is indicated, the proceduralist must either proceed while anticipating the increased bleeding risk or postpone the procedure for several days while accepting the risks associated with delaying a clinically indicated procedure. American College of Cardiology Foundation–American Heart Association, European Society of Cardiology, and other society guidelines recommend cessation of oral P2Y12 receptor antagonists at least 3 to 7 days before surgery.  Currently, no reversal agents for P2Y12 receptor antagonists are known. Unlike the other P2Y12 receptor antagonists, ticagrelor is a reversible inhibitor, which makes the development of a specific reversal agent for ticagrelor feasible.

In this program Drs. Pollack and Bhatt discuss the clinical need for a reversal agent for antiplatelet therapy, as well as an ongoing trial of the first such drug.  They also comment on the difficulties faced by today’s clinical researchers during the ongoing COVID-19 pandemic.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding managing hemorrhagic complications and bleeding risks associated with platelet P2Y12 inhibitor therapy.

Agenda

  1. Inhibiting the Platelet P2Y12 Receptor: Efficacy and Safety
  2. Clinical Perspectives on Bleeding, Bleeding Risk, and Its Management in P2Y12 Inhibition
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a Specific Reversal Agent for a P2Y12 Inhibitor
  4. Challenges in Executing Clinical Trials in the Acute Care Environment

Course Chair

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi

Faculty

Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.
Consultant/Advisor: AstraZeneca Pharmaceuticals

Deepak L. Bhatt, MD, MPH
Grant/Research Support: Abbott; Afimmune Limited; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eli Lilly and Company; Eisai Co., Ltd.; Ethicon Inc.; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon; Medtronic; Pfizer Inc.; PhaseBio Pharmaceuticals; PLx Pharma Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Synaptic; The Medicines Company

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-20-020-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PhaseBio Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PhaseBio Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians, including nurses, NPs, PAs, and pharmacists who manage patients with P2Y12 inhibitor-related bleeding risks.

Learning Objectives

  1. Review the scientific basis for benefit from P2Y12 inhibition as well as the bleeding risks that result from therapy and understand the known epidemiology of clinically significant bleeding complications with these agents
  2. Analyze and understand the different perspectives of various specialists on the chronic use of P2Y12 inhibitor therapy
  3. Review current management strategies for P2Y12 inhibitor-associated bleeding risks, as well as therapies still in development
  4. Review in detail the rationale and methodology of a phase 3 clinical trial that identifies patients suitable for ticagrelor reversal and follow its execution as the science of managing patients with ticagrelor-associated hemorrhage and procedural bleeding risk

Activity Description

Antiplatelet therapy is an essential part of secondary prevention of cardiovascular events.  In particular, dual antiplatelet therapy (DAPT)—the combination of aspirin with an oral P2Y12 receptor antagonist—is the predominant approach in patients with acute coronary syndromes (ACS), coronary-artery stenting, or previous myocardial infarction (MI). The three oral P2Y12 receptor antagonists that are in use are clopidogrel, prasugrel, and ticagrelor.

An unavoidable limitation of all three oral P2Y12 receptor antagonists is increased bleeding risk from platelet inhibition, which persists for several days after drug cessation. Establishment of hemostasis can be challenging in patients with major bleeding, such as intracranial or gastrointestinal hemorrhage. In addition, urgent invasive procedures, especially emergency procedures, are associated with an increased risk of periprocedural bleeding. If an emergency procedure is indicated, the surgeon or proceduralist must proceed while accepting the increased bleeding risk, often after empirically providing platelet transfusions, despite the ineffectiveness of such transfusions in reversing the antiplatelet effects of P2Y12 inhibitors. If an urgent procedure is indicated, the proceduralist must either proceed while anticipating the increased bleeding risk or postpone the procedure for several days while accepting the risks associated with delaying a clinically indicated procedure. American College of Cardiology Foundation–American Heart Association, European Society of Cardiology, and other society guidelines recommend cessation of oral P2Y12 receptor antagonists at least 3 to 7 days before surgery.  Currently, no reversal agents for P2Y12 receptor antagonists are known. Unlike the other P2Y12 receptor antagonists, ticagrelor is a reversible inhibitor, which makes the development of a specific reversal agent for ticagrelor feasible.

In this program Drs. Pollack and Bhatt discuss the clinical need for a reversal agent for antiplatelet therapy, as well as an ongoing trial of the first such drug.  They also comment on the difficulties faced by today’s clinical researchers during the ongoing COVID-19 pandemic.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding managing hemorrhagic complications and bleeding risks associated with platelet P2Y12 inhibitor therapy.

Agenda

  1. Inhibiting the Platelet P2Y12 Receptor: Efficacy and Safety
  2. Clinical Perspectives on Bleeding, Bleeding Risk, and Its Management in P2Y12 Inhibition
  3. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a Specific Reversal Agent for a P2Y12 Inhibitor
  4. Challenges in Executing Clinical Trials in the Acute Care Environment

Course Chair

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi

Faculty

Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)
Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.
Consultant/Advisor: AstraZeneca Pharmaceuticals

Deepak L. Bhatt, MD, MPH
Grant/Research Support: Abbott; Afimmune Limited; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eli Lilly and Company; Eisai Co., Ltd.; Ethicon Inc.; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon; Medtronic; Pfizer Inc.; PhaseBio Pharmaceuticals; PLx Pharma Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Synaptic; The Medicines Company

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-20-020-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PhaseBio Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PhaseBio Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

1.00 CME / CNE / CPE
AcademicCME
Diagnosis and Management of Acquired Methemoglobinemia

Diagnosis and Management of Acquired Methemoglobinemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Emergency medicine physicians, intensivists, toxicologists, infectious disease specialists, oncologists, advanced practitioners, nurses, hospital-based pharmacists, and other healthcare professionals involved in the care of patients with acquired methemoglobinemia.

Learning Objectives

  1. Discuss the pathophysiologic basis of methemoglobinemia, explain the origin of the “saturation gap,” and apply that to diagnostic evaluation
  2. Analyze available data on the various treatment options for acquired methemoglobinemia
  3. Develop therapeutic plans and monitor adverse side effects with the multidisciplinary care team to improve patient outcomes

Activity Description

The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support. There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure. Because acquired methemoglobinemia is rare, clinicians should seek out and pursue education on the most up-to-date information on etiology, diagnosis, and treatment.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with acquired methemoglobinemia.

Agenda

  1. Patient Case 1 Analysis: An Ill Patient with an Oxygen Saturation Gap
  2. Pathophysiology of Acquired Methemoglobinemia: Identifying the Usual Suspects, but in Context
  3. Clinical Strategies to Improve Outcomes in Patients with Acquired Methemoglobinemia
  4. Patient Case 2 Analysis: Acute Decompensation in the ICU
  5. An Interprofessional Approach to Treatment Plan Development & Patient Monitoring

Faculty

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


John Fanikos, RPh, MBA
Executive Director of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts


Frank LoVecchio, DO, MPH, FACEP, ABMT
Professor, Research Scholar, University of Arizona
Emergency Medicine, Medicine and Pharmacology
Tucson, Arizona


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)

Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.

Consultant/Advisor: AstraZeneca Pharmaceuticals

John Fanikos, RPh, MBA

Consultant/Advisor: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; Portola Therapeutics, Inc.; Ipsen Pharmaceuticals, Inc.

Grant/Research Support: Boehringer Ingelheim International GmbH; Heron Therapeutics, Inc.

Frank LoVecchio, DO, MPH, FACEP, ABMT

Grant/Research Support: National Institutes of Health

Speaker’s Bureau: Allergan

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hours, including 1.0 Pharmacotherapeutic Contact Hours (Provider number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hours (0.10 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-012-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PROVEPHARM INC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PROVEPHARM INC. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Emergency medicine physicians, intensivists, toxicologists, infectious disease specialists, oncologists, advanced practitioners, nurses, hospital-based pharmacists, and other healthcare professionals involved in the care of patients with acquired methemoglobinemia.

Learning Objectives

  1. Discuss the pathophysiologic basis of methemoglobinemia, explain the origin of the “saturation gap,” and apply that to diagnostic evaluation
  2. Analyze available data on the various treatment options for acquired methemoglobinemia
  3. Develop therapeutic plans and monitor adverse side effects with the multidisciplinary care team to improve patient outcomes

Activity Description

The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support. There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure. Because acquired methemoglobinemia is rare, clinicians should seek out and pursue education on the most up-to-date information on etiology, diagnosis, and treatment.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with acquired methemoglobinemia.

Agenda

  1. Patient Case 1 Analysis: An Ill Patient with an Oxygen Saturation Gap
  2. Pathophysiology of Acquired Methemoglobinemia: Identifying the Usual Suspects, but in Context
  3. Clinical Strategies to Improve Outcomes in Patients with Acquired Methemoglobinemia
  4. Patient Case 2 Analysis: Acute Decompensation in the ICU
  5. An Interprofessional Approach to Treatment Plan Development & Patient Monitoring

Faculty

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


John Fanikos, RPh, MBA
Executive Director of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts


Frank LoVecchio, DO, MPH, FACEP, ABMT
Professor, Research Scholar, University of Arizona
Emergency Medicine, Medicine and Pharmacology
Tucson, Arizona


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)

Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.

Consultant/Advisor: AstraZeneca Pharmaceuticals

John Fanikos, RPh, MBA

Consultant/Advisor: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; Portola Therapeutics, Inc.; Ipsen Pharmaceuticals, Inc.

Grant/Research Support: Boehringer Ingelheim International GmbH; Heron Therapeutics, Inc.

Frank LoVecchio, DO, MPH, FACEP, ABMT

Grant/Research Support: National Institutes of Health

Speaker’s Bureau: Allergan

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hours, including 1.0 Pharmacotherapeutic Contact Hours (Provider number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hours (0.10 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-012-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PROVEPHARM INC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PROVEPHARM INC. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

1.00 CME / CNE / CPE
American Heart Association
Improving the Care of Patients with Transthyretin Amyloidosis Webinar Series – Emerging Therapies and Treatment Considerations for ATTR Amyloidosis

Improving the Care of Patients with Transthyretin Amyloidosis Webinar Series – Emerging Therapies and Treatment Considerations for ATTR Amyloidosis

Start

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: October 14, 2020
Expires: October 13, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Review the clinical presentation and diagnosis of ATTR amyloidosis.
  2. Discuss the mechanism of pathogenesis in ATTR amyloidosis.
  3. Describe the recent and ongoing clinical trials studying novel ATTR-specific therapies.
  4. Detail pharmacologic treatments for ATTR cardiomyopathy and neuropathy.
  5. Summarize strategies to ensure patient access to ATTR therapies.

Activity Description

The goal of this continuing medical education (CME) webinar is to improve the care of patients with Transthyretin Amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease presentation, pharmacologic treatments and patient access strategies that healthcare professionals can put into practice immediately.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention is to improve the care of patients with Transthyretin Amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Emerging Therapies and Treatment Considerations for ATTR Amyloidosis
10 minutes – Q & A

Presenters

Kevin M. Alexander, MD
Assistant Professor of Medicine
(Cardiovascular Medicine)
Member, Stanford Amyloid Center
Member, Stanford Cardiovascular Institute
Stanford, CA


Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP
Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Assistant Professor of Medicine
Albert Einstein College of Medicine
Bronx, NY

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant – Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 10/14/2020
TERMINATION DATE: 10/13/2023
LAST REVIEW DATE: August 2020
ACCREDITATION TERMS:
Joint Accreditation: 10/14/2020 – 10/13/2023
CAPCE: 10/14/2020 – 10/13/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:
View the content in its entirety.
Complete a post-test with a minimum score of 80%.
Complete a survey of your learning experience.
Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: October 14, 2020
Expires: October 13, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Review the clinical presentation and diagnosis of ATTR amyloidosis.
  2. Discuss the mechanism of pathogenesis in ATTR amyloidosis.
  3. Describe the recent and ongoing clinical trials studying novel ATTR-specific therapies.
  4. Detail pharmacologic treatments for ATTR cardiomyopathy and neuropathy.
  5. Summarize strategies to ensure patient access to ATTR therapies.

Activity Description

The goal of this continuing medical education (CME) webinar is to improve the care of patients with Transthyretin Amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease presentation, pharmacologic treatments and patient access strategies that healthcare professionals can put into practice immediately.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention is to improve the care of patients with Transthyretin Amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Emerging Therapies and Treatment Considerations for ATTR Amyloidosis
10 minutes – Q & A

Presenters

Kevin M. Alexander, MD
Assistant Professor of Medicine
(Cardiovascular Medicine)
Member, Stanford Amyloid Center
Member, Stanford Cardiovascular Institute
Stanford, CA


Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP
Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Assistant Professor of Medicine
Albert Einstein College of Medicine
Bronx, NY

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant – Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 10/14/2020
TERMINATION DATE: 10/13/2023
LAST REVIEW DATE: August 2020
ACCREDITATION TERMS:
Joint Accreditation: 10/14/2020 – 10/13/2023
CAPCE: 10/14/2020 – 10/13/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:
View the content in its entirety.
Complete a post-test with a minimum score of 80%.
Complete a survey of your learning experience.
Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org

1.00 CME / CNE / CPE
American Heart Association
Improving the Care of Patients with Transthyretin Amyloidosis Webinar Series – Hidden in Plain Sight: The Clinical Presentation of ATTR

Improving the Care of Patients with Transthyretin Amyloidosis Webinar Series – Hidden in Plain Sight: The Clinical Presentation of ATTR

Start

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: July 15, 2020
Expires: July 14, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Describe the epidemiology and demography of wild-type and hereditary ATTR amyloidosis with review of special populations in whom the disease is more prevalent.
  2. Recognize the pathophysiology that leads to amyloid deposition in different organ systems, forming the basis for understanding treatment approaches.
  3. Describe the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys.
  4. Outline the diagnostic approach to follow when treating a patient with suspected ATTR amyloidosis with focus on imaging and scenarios that require invasive biopsy.

Activity Description

The purpose of this webinar is to discuss the epidemiology and demography of wild-type and hereditary ATTR amyloidosis, with a review of special populations in whom the disease is more prevalent, as well as insights into the pathophysiology that leads to amyloid deposition in different organ systems, such as the heart, nervous system, gastro-intestinal tract, and kidneys, forming the basis for understanding treatment approaches.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention project is to improve the care of patients with transthyretin amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Hidden in Plain Sight: The Clinical Presentation of ATTR
10 minutes – Q & A

Presenters

Frederick (Rick) L. Ruberg, MD
Director, Advanced Cardiovascular Imaging
Associate Professor of Medicine
Program Associate Director, Cardiovascular
Boston University School of Medicine
Boston, MA


Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
Family Medicine
University of Florida
Gainesville, FL

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant - Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 07/15/2020
TERMINATION DATE: 07/14/2023
LAST REVIEW DATE: July 2020
ACCREDITATION TERMS:
Joint Accreditation: 07/15/2020 – 07/14/2023
CAPCE: 07/15/2020 – 07/14/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:

View the content in its entirety.

Complete a post-test with a minimum score of 75%.

Complete a survey of your learning experience.

Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org

Activity Details

Free CME/CNE/CPE
1.00 AMA PRA Category 1 Credit(s)
1.00 Contact Hour(s)
Released: July 15, 2020
Expires: July 14, 2023
60 minutes to complete

Accredited By

Target Audience

Cardiologists, Heart Failure Specialists, Neurologists, Echocardiographers, and Primary Care physicians who are involved in the care of patients with ATTR amyloidosis.

Learning Objectives

  1. Describe the epidemiology and demography of wild-type and hereditary ATTR amyloidosis with review of special populations in whom the disease is more prevalent.
  2. Recognize the pathophysiology that leads to amyloid deposition in different organ systems, forming the basis for understanding treatment approaches.
  3. Describe the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys.
  4. Outline the diagnostic approach to follow when treating a patient with suspected ATTR amyloidosis with focus on imaging and scenarios that require invasive biopsy.

Activity Description

The purpose of this webinar is to discuss the epidemiology and demography of wild-type and hereditary ATTR amyloidosis, with a review of special populations in whom the disease is more prevalent, as well as insights into the pathophysiology that leads to amyloid deposition in different organ systems, such as the heart, nervous system, gastro-intestinal tract, and kidneys, forming the basis for understanding treatment approaches.

Statement of Educational Need

The overall goal of AHA Lifelong Learning’s proposed continuing medical education (CME) intervention project is to improve the care of patients with transthyretin amyloidosis (ATTR amyloidosis) by closing practice and knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment models that healthcare professionals can put into practice immediately.

Agenda

50 minutes – Hidden in Plain Sight: The Clinical Presentation of ATTR
10 minutes – Q & A

Presenters

Frederick (Rick) L. Ruberg, MD
Director, Advanced Cardiovascular Imaging
Associate Professor of Medicine
Program Associate Director, Cardiovascular
Boston University School of Medicine
Boston, MA


Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
Family Medicine
University of Florida
Gainesville, FL

Faculty

Frederick L. Ruberg, MD
Jose Nativi-Nicolau, MD
Louis Kuritzky, MD
Kevin M. Alexander, MD
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represents the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Frederick L. Ruberg, MD – Research Grant – Pfizer Inc., Akcea Therapeutics, Eidos Therapeutics
Jose Nativi-Nicolau, MD – Research Grant – Pfizer, Akcea, Gidos; Consultant/Advisory Board – Pfizer, Akcea, Alnylam; Other – Educational Grant - Pfizer
Louis Kuritzky, MD – No Disclosures
Kevin M. Alexander, MD – No Disclosures
Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN – No Disclosures
Katherine E. DiPalo, PharmD, FAHA, BCACP, BCGP – No Disclosures

Accreditation Statement

ORIGINAL RELEASE DATE: 07/15/2020
TERMINATION DATE: 07/14/2023
LAST REVIEW DATE: July 2020
ACCREDITATION TERMS:
Joint Accreditation: 07/15/2020 – 07/14/2023
CAPCE: 07/15/2020 – 07/14/2023

In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.00 hours of Category I credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact hours.

ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program Number: JA0000134-0000-20-036-H04-P

Participation and Successful Completion

Successful completion of this CE activity includes the following:

View the content in its entirety.

Complete a post-test with a minimum score of 75%.

Complete a survey of your learning experience.

Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Pfizer, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions About the Activity

Luci Ochoa, MBA
Manager, Professional Education, AHA National Center
luci.ochoa@heart.org